Sources and References

Primary textbook — Compendium of Therapeutics for Minor Ailments. Ottawa, ON: Canadian Pharmacists Association. Available online at https://myrxtx.ca/search.

Supplementary texts — Krinsky DL, Berardi RR, Ferrari SP, et al. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 21st ed. American Pharmaceutical Association, 2024. Herrier R, Apgar D, Boyce R, Foster S. Patient Assessment in Pharmacy. McGraw-Hill Education, 2015.

Online resources — Health Canada Drug Product Database (https://health-canada.ca); NAPRA National Drug Scheduling System (https://www.napra.ca); Ontario College of Pharmacists Minor Ailments information (https://www.ocpinfo.com); Society of Obstetricians and Gynaecologists of Canada (SOGC) guidelines (https://www.jogc.com); Canadian Dermatology Association guidelines; Infectious Diseases Society of America (IDSA) guidelines; Gastroenterological Association of Canada (CAG) guidelines; WHO safe motherhood and reproductive health resources.

Chapter 1: Foundations of Advanced Patient Self Care — Levelling Up Minor Ailment Practice

The Evolving Role of the Pharmacist in Self-Care

Advanced Patient Self-Care builds directly on foundational pharmacology and therapeutics to develop highly nuanced clinical competencies in the assessment and management of patients presenting with self-care concerns across a remarkably diverse range of clinical contexts. Where earlier courses introduced the conceptual underpinnings of pharmacist consultation for minor ailments, PHARM 362 demands a more sophisticated level of integration — the pharmacist must not only know which OTC product to recommend for a sore throat, but must be capable of distinguishing acute pharyngitis requiring antibiotic treatment from viral pharyngitis requiring symptomatic care, of recognizing when pharyngitis is a presentation of an underlying condition requiring referral (infectious mononucleosis, peritonsillar abscess, epiglottitis), and of providing evidence-based, patient-centred care that acknowledges the patient’s individual circumstances, values, and health literacy.

The Pharmacists’ Patient Care Process (PPCP) — collect, assess, plan, implement, follow up — is the overarching framework within which all self-care consultations should be organized. Applied to minor ailments, this means resisting the temptation to immediately match a presenting complaint to a product and instead systematically collecting information that allows accurate clinical assessment: the nature, onset, duration, severity, and modifying factors of the presenting symptom; associated symptoms that may indicate severity or a systemic process; the patient’s relevant medical history and current medications; allergies and previous treatment responses; and psychosocial factors such as pregnancy status, breastfeeding, age, immunocompromised status, and health literacy. Only after this systematic assessment can the pharmacist move to planning — determining whether self-care is appropriate, selecting the optimal evidence-based treatment, and counselling the patient on self-monitoring and referral triggers.

The expansion of pharmacist minor ailment prescribing in Canada — most significantly the implementation of the Ontario Pharmacy Act Regulation authorizing pharmacists to prescribe for 19 minor ailments since January 2023 — fundamentally changes the self-care consultation. The pharmacist is no longer limited to recommending OTC products; they can assess the patient, arrive at a clinical assessment, and prescribe first-line prescription products (such as trimethoprim-sulfamethoxazole for uncomplicated urinary tract infections, fluconazole for vaginal candidiasis, or hormonal contraception for emergency contraception) when clinically appropriate. This expanded scope requires commensurately advanced clinical assessment skills, documentation practices, and awareness of when prescription management is appropriate versus when referral is needed. The clinical competencies developed in PHARM 362 provide the foundation for confident, safe, and effective minor ailment prescribing.

The Pharmacists’ Patient Care Process Applied to Minor Ailments

The PPCP in the minor ailment context begins with a structured, efficient patient interview — one that gathers the necessary clinical information while respecting the patient’s time and comfort. A widely used framework for organizing the clinical interview in self-care practice is the SCHOLAR-MAC acronym: Symptoms (nature and character of the presenting complaint), Characteristics (specific features — quality, quantity, severity on a 0-10 scale), History (onset and duration — is this a new problem or a recurrence?), Onset (sudden vs. gradual, relationship to triggering events), Location (anatomical site, radiation, distribution), Aggravating and Alleviating factors, Remissions (does the symptom come and go?), and Medications (current prescription and OTC medications, supplements, vitamins, herbal products), Allergies (drug allergies and sensitivities), and Conditions (relevant past and current medical conditions).

Documentation of minor ailment consultations is a professional and regulatory obligation. The Ontario College of Pharmacists requires that pharmacists document minor ailment prescribing encounters, including the patient’s presenting complaint, the clinical assessment, the prescription or recommendation made, and the follow-up plan. This documentation serves multiple purposes: it supports continuity of care if the patient presents to another health provider; it provides a medico-legal record of the clinical encounter; it enables quality improvement audits; and it supports communication with the patient’s primary care provider, to whom a clinical summary should be sent when a minor ailment is managed independently. Developing efficient, accurate documentation practices from the outset of minor ailment prescribing practice is essential for managing the administrative burden of this expanded scope while maintaining the clinical quality that patients expect.

Chapter 2: Reproductive and Sexual Health — Emergency Contraception

Mechanism and Pharmacology of Emergency Contraception Options

Emergency contraception (EC) refers to methods used to prevent pregnancy after unprotected sexual intercourse or contraceptive failure. In the Canadian pharmacy context, the two main types of EC available for pharmacist management are levonorgestrel-containing tablets (Plan B, Next Choice, and generics) and the selective progesterone receptor modulator ulipristal acetate (Ella/Fibristal). The copper intrauterine device (Cu-IUD) is the most effective EC method but requires placement by a trained healthcare provider and is not typically within the pharmacist’s prescribing scope.

Levonorgestrel EC works primarily by inhibiting or delaying ovulation. Levonorgestrel at the doses used in EC (1.5 mg as a single dose) dramatically suppresses the LH surge that triggers ovulation; if taken before or at the time of the LH surge, it prevents follicular rupture and therefore prevents fertilization of an egg. The evidence strongly supports ovulation inhibition as the primary mechanism; there is limited evidence that levonorgestrel EC reliably prevents pregnancy after ovulation has occurred. This mechanistic distinction is important for counselling patients who have concerns about EC’s mechanism of action based on religious or ethical beliefs. Levonorgestrel EC is most effective when taken within 72 hours of unprotected sex and loses efficacy progressively with time; it is authorized for use up to 72 hours and off-label use up to 120 hours (5 days) is also practised, though efficacy at 72-120 hours is lower. Body weight substantially modifies levonorgestrel EC efficacy: clinical evidence suggests that levonorgestrel EC may be significantly less effective in women weighing more than 75 kg (165 lbs) and potentially ineffective above 80 kg (176 lbs), where ulipristal acetate is preferred.

Ulipristal acetate (UPA, Ella/Fibristal) is a selective progesterone receptor modulator that inhibits or delays ovulation by modulating progesterone receptor function in the pituitary-hypothalamic axis. Unlike levonorgestrel, UPA can inhibit follicular rupture even after the LH surge has begun, making it effective even when taken closer to the time of ovulation. UPA is authorized for use up to 120 hours (5 days) after unprotected sex and maintains its efficacy more uniformly across this 120-hour window than levonorgestrel; it is also more effective than levonorgestrel in overweight and obese women. Because UPA is a progesterone receptor modulator, it should not be taken within 5 days of using progestogen-containing contraceptives (which could antagonize its effects), and progestogen-containing contraceptives should not be started within 5 days of UPA use. In Ontario, UPA requires a prescription; in the minor ailment prescribing framework, pharmacists can prescribe either levonorgestrel EC (which is Schedule III, pharmacist-supervised sale) or UPA (prescription) depending on clinical assessment.

Pelvic Pain — Assessment and Differential Diagnosis

Pelvic pain in individuals with female anatomy is among the more diagnostically complex presentations a pharmacist may encounter in the self-care setting, because the list of potential causes ranges from minor, self-limiting conditions that are entirely appropriate for self-care management to acute surgical emergencies requiring immediate referral. The pharmacist’s role is not to diagnose the cause of pelvic pain but to conduct a systematic assessment that identifies the clinical features consistent with self-care-appropriate conditions and to recognize the red flag symptoms that demand urgent referral.

Primary dysmenorrhea — pelvic pain occurring cyclically with menstruation in the absence of pelvic pathology — is the most common cause of pelvic pain in reproductive-age individuals and is eminently appropriate for pharmacist-led management. The pathophysiology involves excessive uterine prostaglandin production (particularly PGF2-alpha and PGE2) in the secretory endometrium, stimulating uterine smooth muscle contractions that cause ischemia and pain. NSAIDs — inhibitors of cyclooxygenase (COX) enzymes that synthesize prostaglandins from arachidonic acid — are the first-line pharmacological treatment for primary dysmenorrhea, with strong evidence from multiple RCTs showing superiority over placebo and acetaminophen. Ibuprofen (400-600 mg every 4-6 hours, maximum 1200 mg/day OTC), naproxen sodium (220-440 mg initially then 220 mg every 8-12 hours, maximum 660 mg/day OTC), and other NSAIDs provide substantial pain relief when initiated at or just before menstrual flow onset. Combined oral contraceptives are highly effective for severe or refractory dysmenorrhea because they suppress ovulation and reduce prostaglandin-inducing endometrial proliferation, but they require prescription management.

Red flag features that mandate referral and exclude pharmacist minor ailment management of pelvic pain include: pelvic pain that is not clearly cycle-associated or that is new or worsening in character (may indicate pelvic inflammatory disease, ovarian cyst complication, appendicitis, or other pathology); fever or vaginal discharge suggesting infection; pain of sudden onset with collapse or syncope (suggesting ruptured ectopic pregnancy or ovarian cyst — a medical emergency); pain associated with urinary or bowel symptoms suggesting involvement of adjacent organs; pain in pregnancy or suspected pregnancy; and pain that has not responded to adequate OTC NSAID therapy after two to three cycles (suggesting endometriosis or another pathological cause requiring gynecological evaluation).

Chapter 3: Perinatal Nutrition and Breastfeeding Support

Nutrition During Pregnancy — Clinical Pharmacist Role

Pregnancy creates substantially increased nutritional demands as the developing fetus draws on maternal stores and dietary intake for all of its macronutrient and micronutrient needs. The pharmacist in a community or clinical setting has an important role in counselling pregnant patients about nutritional supplementation, identifying potential drug-nutrient interactions, and recognizing signs of nutritional deficiency that warrant referral.

Folic acid supplementation before and during the first trimester of pregnancy is one of the most robustly evidence-based interventions in perinatal care. Folate (the natural form found in food; folic acid is the synthetic form used in supplements) is required for DNA synthesis and cell division; deficiency in the critical early weeks of neural tube development (weeks 3-4 post-conception, before most women know they are pregnant) causes neural tube defects (NTDs) — severe congenital abnormalities of the spinal cord and brain including spina bifida and anencephaly. Health Canada, SOGC, and other authorities recommend that all individuals who may become pregnant take a daily supplement containing 0.4-1.0 mg of folic acid for at least 3 months before conception and throughout the first trimester. Women at high risk of NTD (personal or family history of NTD, diabetes, obesity, use of folate-antagonist medications such as methotrexate, valproic acid, or trimethoprim) are recommended to take 4 mg/day of folic acid, initiated at least 3 months before conception — a dose that requires a prescription in Canada (available as 5 mg tablets). The pharmacist has a critical role in identifying women of reproductive age on folate-antagonist medications and ensuring they are taking appropriate folic acid supplementation.

Iron-deficiency anemia in pregnancy is extremely common — affecting 15-25% of pregnant people in Canada — because maternal iron requirements increase substantially during pregnancy to support the expansion of maternal erythrocyte mass (requiring approximately 500 mg of additional iron) and fetal and placental development (requiring approximately 300-350 mg). The recommended daily intake of iron increases from 18 mg/day in non-pregnant adult women to 27 mg/day during pregnancy. Most prenatal vitamins provide 27 mg of elemental iron per tablet, which is sufficient for women entering pregnancy with adequate iron stores, but inadequate for those who are already iron-depleted. Symptoms of iron deficiency anemia in pregnancy — fatigue, dyspnea on exertion, pallor, palpitations — can overlap substantially with normal pregnancy symptoms, making laboratory diagnosis (serum ferritin as the most sensitive marker, followed by hemoglobin and mean corpuscular volume) essential for accurate diagnosis.

Breastfeeding Support — Pharmacological and Practical Considerations

Breastfeeding provides optimal nutrition for infants and confers significant health benefits to both the infant (reduced incidence of otitis media, respiratory infections, gastrointestinal infections, obesity, type 2 diabetes, and sudden infant death syndrome) and the mother (reduced risk of breast and ovarian cancer, type 2 diabetes, postpartum depression, and osteoporosis). Health Canada, the Canadian Pediatric Society, and the World Health Organization all recommend exclusive breastfeeding for the first 6 months of life, with continued breastfeeding to 2 years or beyond alongside appropriate complementary foods. Despite this strong policy support, breastfeeding rates decline rapidly after hospital discharge, and pharmacists are well-positioned to support breastfeeding parents through accurate medication counselling and evidence-based practical advice.

Drug use during lactation requires careful consideration of the drug’s characteristics — its molecular weight (smaller molecules cross into breast milk more easily), protein binding (drugs with high protein binding have lower free concentrations available for transfer into milk), lipid solubility (lipophilic drugs concentrate in the lipid-rich fat fraction of milk), and oral bioavailability in the infant (a drug that crosses into milk but is poorly absorbed orally by the infant will produce minimal systemic exposure). The relative infant dose (RID) — calculated as the infant’s daily dose through breast milk (mg/kg/day) divided by the maternal dose (mg/kg/day) — is the most commonly used metric for assessing drug safety during lactation. An RID below 10% is generally considered acceptable from a safety standpoint, though this threshold must be interpreted in the context of the drug’s known toxicity profile, the infant’s age and health status, and the importance of breastfeeding to that family.

Chapter 4: Dermatology — Skin Assessment in Diverse Populations

Approach to Dermatologic Assessment — Skin of Colour

Dermatologic assessment in pharmacy practice has traditionally been taught and illustrated using examples from patients with lighter skin tones, creating gaps in training that can result in missed or delayed diagnoses in patients with darker skin tones (Fitzpatrick skin types IV-VI). The skin of colour movement in dermatology has increasingly documented that many dermatologic conditions present differently in darker skin — and that the failure to recognize these presentations contributes to health disparities in dermatologic care.

Erythema (redness), the most common descriptor of skin inflammation across dermatology, appears as bright red or pink in Fitzpatrick type I-III skin but may appear brown, violaceous, grey, or subtly darker in Fitzpatrick type IV-VI skin. This means that conditions diagnosed primarily by their erythematous appearance — cellulitis, contact dermatitis, eczema, rosacea — may be missed or misidentified in patients with darker skin if the clinician relies solely on redness as an indicator of inflammation. Palpation for warmth, asking about subjective symptoms (itch, burning, tightness), and attention to textural changes (scaling, crusting, lichenification) provide clinical information that is not skin-tone-dependent and should be integrated into all dermatologic assessments regardless of the patient’s skin tone.

Post-inflammatory hyperpigmentation (PIH) — darkening of the skin at sites of prior inflammation — is a disproportionately significant concern for patients with Fitzpatrick type IV-VI skin, because melanin-producing melanocytes in darker skin respond more robustly to inflammatory stimuli. Conditions that are considered relatively minor in lighter skin — mild acne, insect bites, contact dermatitis — can leave lasting dark patches on darker skin that are cosmetically and psychologically significant, sometimes more so than the original condition. Pharmacists advising patients with darker skin on self-care for inflammatory skin conditions should explicitly discuss the risk of PIH, the importance of sun protection (UV exposure intensifies PIH by stimulating additional melanogenesis), and management options for established PIH (topical vitamin C, niacinamide, azelaic acid, kojic acid, alpha-arbutin).

Seborrheic Dermatitis — Pathophysiology and Self-Care Management

Seborrheic dermatitis is a chronic, relapsing inflammatory skin condition affecting areas rich in sebaceous glands — the scalp, face (particularly the eyebrows, nasolabial folds, glabella, and external ear canals), and presternal chest. It affects approximately 1-3% of the general population and up to 5% of adults, with significantly higher prevalence (up to 35%) in immunocompromised individuals, particularly those with HIV infection where seborrheic dermatitis correlates with CD4 cell count decline and can serve as a marker of disease progression. The condition is chronic and non-curable but highly manageable with appropriate treatment.

The pathophysiology of seborrheic dermatitis involves the interplay of three factors: the lipophilic yeast Malassezia (formerly Pityrosporum), present on most human skin as part of the normal cutaneous microbiome; sebum, which Malassezia metabolizes by secreting lipases that cleave oleic acid from triglycerides; and an individual’s immunological response to Malassezia and its metabolites, which triggers the inflammatory cascade responsible for erythema, scaling, and pruritus. Not all individuals colonized by Malassezia develop seborrheic dermatitis — susceptibility depends on host immune and inflammatory factors — which explains why antifungal therapy controls the yeast but does not cure the condition; the disease recurs when treatment is stopped because the yeast remains.

First-line OTC treatment for scalp seborrheic dermatitis involves antidandruff shampoos containing active ingredients targeting Malassezia or the inflammatory response. Zinc pyrithione (Head & Shoulders, others) has antifungal and antibacterial activity and is among the best-studied antidandruff ingredients, with clinical trials demonstrating significant reduction in dandruff severity with regular use. Selenium sulfide (Selsun Blue, Selsun) inhibits skin cell turnover and has antifungal activity; it is more potent than zinc pyrithione and is appropriate for more severe cases. Ketoconazole 1% shampoo (Nizoral A-D) is available OTC in Canada and is specifically antifungal; it is effective for seborrheic dermatitis with a strong evidence base. Coal tar preparations slow skin cell turnover and reduce scaling; they are cosmetically less acceptable than other options (odour, potential staining of hair) and are used less frequently. Salicylic acid-containing shampoos are keratolytic and help dissolve and remove scale but do not address the underlying inflammatory or yeast component. For facial seborrheic dermatitis, OTC options include antifungal shampoos used as brief-contact treatments and hydrocortisone 0.5-1% cream for inflammatory flares.

Cutaneous Candidiasis and Dermatophytosis

Superficial fungal infections of the skin — caused by Candida species (cutaneous candidiasis) or by dermatophyte fungi (Trichophyton, Microsporum, Epidermophyton species — tinea infections) — are among the most common dermatological complaints presenting to pharmacies. Distinguishing between these two categories of fungal infection is clinically important because they may have different presentations, overlapping anatomical distributions, and subtly different treatment responses, and because the drug choices for each are well-established.

Topical azole antifungals — clotrimazole (Canesten), miconazole (Monistat, Micatin), tioconazole — are the OTC first-line treatment for both dermatophytosis (tinea) and cutaneous candidiasis; they inhibit ergosterol synthesis in fungal cell membranes by blocking the CYP51 enzyme (lanosterol 14-alpha-demethylase). Terbinafine (Lamisil) cream and spray are also OTC available and are allylamine antifungals that inhibit squalene epoxidase, a different enzyme in the ergosterol synthesis pathway; terbinafine is fungicidal (kills the fungus) rather than merely fungistatic (inhibits growth) for dermatophytes, and may produce faster cure rates for tinea pedis and other dermatophyte infections — though for most superficial skin tinea, the clinical difference between azoles and terbinafine is modest. The critical counselling points for topical antifungal therapy are: apply to affected area and 1-2 cm of surrounding skin; continue for the recommended duration (typically 2-4 weeks for skin infections) even after symptoms resolve, as premature discontinuation leads to relapse; keep the area dry; and avoid occlusive dressings that maintain moisture.

Chapter 5: Gastrointestinal Self Care

Irritable Bowel Syndrome — Assessment and Management

Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders, affecting an estimated 13-20% of Canadians at some point in their lives. It is characterized by recurrent abdominal pain associated with altered bowel habits — in the absence of structural or biochemical abnormalities that would explain the symptoms. Diagnosis in the clinical setting is based on the Rome IV criteria: recurrent abdominal pain at least one day per week in the last three months, associated with two or more of: (1) related to defecation; (2) associated with a change in stool frequency; (3) associated with a change in stool consistency (form). IBS is classified into subtypes based on the predominant bowel habit: IBS-C (constipation predominant), IBS-D (diarrhea predominant), IBS-M (mixed), and IBS-U (unclassified).

The pathophysiology of IBS is complex and multifactorial, involving dysregulation of the gut-brain axis, altered intestinal motility, visceral hypersensitivity (heightened pain perception from gut stimuli that would not be painful in healthy individuals), intestinal microbiome dysbiosis, low-grade mucosal inflammation, and psychological factors including anxiety, depression, and post-traumatic stress. Post-infectious IBS (PI-IBS), developing after acute gastroenteritis, accounts for approximately 10% of IBS cases and is an important subtype to recognize because it has a specific temporal relationship to an infectious trigger and tends to be self-limiting over 1-3 years. The pharmacist must recognize that IBS is a legitimate biological condition — not merely “stress” or a psychosomatic problem — while also understanding that psychological factors substantially modify symptom severity and treatment response.

Self-care for IBS is appropriate for patients with established diagnosis, mild-to-moderate symptom severity, and absence of alarm features. Red flags that mandate urgent referral include: age of onset over 50 years (where new IBS symptoms require exclusion of colorectal cancer); unexplained weight loss; rectal bleeding; family history of colorectal cancer or inflammatory bowel disease; fever; progressive worsening of symptoms; and nocturnal symptoms that awaken the patient from sleep (uncommon in IBS, more typical of inflammatory bowel disease). Self-care recommendations in IBS are highly symptom-subtype specific.

For IBS-C, first-line non-pharmacological recommendations include adequate dietary fibre intake (targeting 25-35 g/day from food sources or supplements), adequate fluid intake, and regular physical activity. Soluble fibre (psyllium, available as Metamucil and generics) is the OTC agent with the best evidence in IBS-C; it absorbs water to form a gel that softens stool and supports regularity, and it may also modestly reduce abdominal pain. Insoluble fibre (wheat bran) may worsen bloating and pain in some IBS patients and is less recommended. Polyethylene glycol (PEG, Lax-A-Day, Restoralax) is an osmotic laxative with good safety data and is effective for improving stool consistency and frequency in IBS-C; stimulant laxatives (bisacodyl, senna) should be used only for occasional relief and not chronically because of the risk of laxative dependence. For IBS-D, loperamide (Imodium) reduces bowel frequency and urgency and is appropriate for occasional use; peppermint oil (in enteric-coated form — IBgard or Pepogest — to avoid gastroesophageal reflux from rapid dissolution in the stomach) has evidence from small RCTs for reducing global IBS symptoms and abdominal pain, likely through calcium channel antagonism in intestinal smooth muscle and activation of TRPM8 cold receptors.

Pinworm Infection — Diagnosis, Treatment, and Prevention

Enterobius vermicularis (pinworm) infection is the most common intestinal parasitic infection in Canada and the United States, predominantly affecting children 5-14 years old but commonly spreading to entire households because the infection is highly contagious. Pinworm infections are entirely appropriate for pharmacist-led self-care management in most cases and represent a frequent community pharmacy consultation.

The life cycle of pinworm is distinctive: adult female worms, residing in the colon, migrate to the perianal skin at night to deposit eggs, causing intense perianal pruritus that is characteristically worse at night and disrupts sleep. The eggs are remarkably resistant in the environment — surviving on bedding, clothing, and surfaces for up to three weeks — and are easily ingested via hand-to-mouth transmission, explaining why household spread is almost universal when one family member is infected. Diagnosis is clinical based on the characteristic history; the “tape test” (applying clear tape to the perianal skin in the morning before bathing and examining it microscopically for eggs) can confirm the diagnosis but is not required for empirical treatment.

Mebendazole (Vermox, 100 mg single dose repeated in 2 weeks) and pyrantel pamoate (Combantrin, 11 mg/kg single dose to maximum 1 g, repeated in 2 weeks) are the two OTC anthelmintic options available in Canada. Both are highly effective for pinworm infection. Mebendazole inhibits beta-tubulin polymerization in nematodes, disrupting the microtubule-dependent glucose uptake processes essential for worm energy metabolism; at approved doses for intestinal nematodes, systemic absorption is minimal (less than 10%), limiting systemic adverse effects. Pyrantel pamoate is a depolarizing neuromuscular blocking agent in nematodes — it acts as an agonist at acetylcholine receptors, causing spastic paralysis of the worm followed by expulsion. The two-dose regimen (initial dose plus repeat at 2 weeks) is essential because neither drug is effective against eggs, only against larvae and adult worms; the second dose eliminates worms that hatched from eggs surviving the first treatment. Treatment of all household members simultaneously — regardless of symptoms, because asymptomatic carriage is common — is recommended to prevent reinfection. Environmental hygiene measures (washing bedding in hot water, daily bathing, nail trimming, washing hands after defecation and before food preparation) are important adjuncts to pharmacological treatment.

Chapter 6: Infectious Disease — Minor Ailment Prescribing

Uncomplicated Urinary Tract Infection — Assessment and Management

Urinary tract infection (UTI) is among the most common bacterial infections in women and one of the conditions most frequently managed through pharmacist minor ailment prescribing in Canadian provinces that have authorized this scope. Approximately 50-60% of women will experience at least one UTI in their lifetime, and recurrent UTI (two or more episodes in six months, or three or more in twelve months) affects approximately 25% of women who have had an initial UTI. The clinical presentation of uncomplicated lower UTI (acute cystitis) — dysuria (painful urination), urinary frequency, urinary urgency, and suprapubic discomfort in the absence of fever or systemic symptoms — is highly predictive of bacterial infection in reproductive-age women with no complicating factors.

The distinction between uncomplicated and complicated UTI is critical for determining appropriateness for pharmacist minor ailment management. Uncomplicated cystitis in non-pregnant women without structural urinary tract abnormalities, diabetes, or immune compromise can be safely managed by a pharmacist with empirical antibiotic therapy without urine culture, because the causative organisms (predominantly Escherichia coli, accounting for 80-85% of cases, followed by Staphylococcus saprophyticus in young women, Klebsiella pneumoniae, Proteus mirabilis, and Enterococcus faecalis) and their antimicrobial susceptibility patterns are predictable. Complicated UTI — occurring in men, in pregnant women, in patients with urological abnormalities (anatomical malformations, renal stones, urinary catheters, prior urological surgery), in patients with renal transplants, in immunocompromised patients, or in association with systemic symptoms (fever above 38°C, chills, rigors, flank pain, costovertebral angle tenderness suggesting upper UTI/pyelonephritis) — requires physician assessment, urine culture, and potentially parenteral antibiotics.

First-line antibiotic therapy for uncomplicated cystitis in Canadian women is guided by local antimicrobial susceptibility data and the principles of antibiotic stewardship. Nitrofurantoin (macrocrystals, 100 mg twice daily for 5 days; or macrocrystal monohydrate, 100 mg twice daily for 5 days) is recommended as the preferred first-line agent in most Canadian guidelines because of its excellent efficacy, low rates of resistance among uropathogenic E. coli in most Canadian communities (resistance below 5% in most surveillance studies), and minimal impact on the gut microbiome (nitrofurantoin achieves therapeutic concentrations only in the urinary tract, not in the gastrointestinal tract). Adverse effects include nausea and vomiting (minimized by taking with food), and rarely pulmonary reactions (eosinophilic pneumonitis — more common with chronic prophylactic use). Nitrofurantoin is contraindicated in patients with CrCl below 30-45 mL/min (depending on guideline) because drug concentrations in the urinary tract are insufficient to treat infection, and drug accumulates systemically. Trimethoprim-sulfamethoxazole (TMP-SMX, Septra DS, one double-strength tablet twice daily for 3 days) is an alternative first-line agent, but its use should be limited to areas where resistance rates are below 20% (which is not universal in Canadian urban centres). Fluoroquinolones (ciprofloxacin, norfloxacin) should not be used as first-line therapy for uncomplicated UTI — their broad spectrum and propensity to cause collateral damage (promoting selection of resistant organisms, disrupting the gut microbiome, risk of Clostridioides difficile colitis) means they should be reserved for complicated infections, pyelonephritis, and situations where first-line agents cannot be used.

Acute Bacterial Pharyngitis — The Strep Throat Dilemma

Acute pharyngitis — sore throat with pharyngeal inflammation — is one of the most common acute presentations in primary care, accounting for millions of physician and pharmacist consultations annually. The clinical challenge for the pharmacist is distinguishing the minority of cases caused by Group A Streptococcus pyogenes (GAS), which benefit from antibiotic treatment, from the majority caused by viruses (rhinovirus, adenovirus, EBV, influenza, others), which do not. Inappropriate antibiotic prescribing for viral pharyngitis is a significant driver of antimicrobial resistance, and a major driver of urgent care visits — pharmacist assessment of pharyngitis is an opportunity to improve antibiotic stewardship at the community level.

The Centor criteria (modified McIsaac criteria) are the most widely used clinical decision tool for GAS pharyngitis probability assessment: tonsillar exudate or swelling (+1), tender anterior cervical lymphadenopathy (+1), fever above 38°C (+1), absence of cough (+1), and patient age 3-14 years (+1) or 45+ years (-1). A total score of 4 or 5 suggests GAS probability of approximately 51-53%; a score of 3 suggests 32-35%; a score of 1-2, less than 15%; and a score of 0 or less, less than 2-3%. Current guidelines recommend: score 4 or 5 — treat empirically or test first; score 2-3 — perform rapid antigen detection test (RADT) and treat only if positive; score 0-1 — no testing or treatment needed.

In Ontario’s minor ailment prescribing framework, pharmacists are authorized to assess and prescribe for acute bacterial pharyngitis using the Centor/McIsaac criteria and, in most protocols, a rapid strep RADT (which pharmacies can perform using CLIA-waived point-of-care testing). First-line antibiotic therapy for confirmed GAS pharyngitis is amoxicillin (500 mg twice daily for 10 days, or 1000 mg once daily for 10 days) or penicillin V (500 mg twice daily or three times daily for 10 days) — a 10-day course is required to eradicate GAS from the oropharynx and reduce the risk of non-suppurative complications (acute rheumatic fever, post-streptococcal glomerulonephritis). For penicillin-allergic patients, azithromycin (500 mg on day 1, then 250 mg once daily for days 2-5) or clarithromycin (250 mg twice daily for 10 days) are alternatives; cephalosporins (cefalexin) are acceptable alternatives in non-anaphylactic penicillin allergy.

Herpes Zoster — Recognition and Minor Ailment Management

Herpes zoster (shingles) results from reactivation of varicella-zoster virus (VZV) that has remained latent in dorsal root ganglia since primary varicella infection. Reactivation occurs when cell-mediated immunity to VZV declines sufficiently to allow viral replication — typically in individuals over 50 years of age, in immunocompromised patients (those on systemic corticosteroids, cancer chemotherapy, biologics, or with HIV infection), and occasionally in younger healthy individuals. The incidence of herpes zoster increases markedly with age, rising from approximately 4 cases per 1000 person-years at ages 50-59 to over 10 per 1000 person-years at ages 70 and older.

The clinical presentation of herpes zoster is characteristic: prodromal symptoms of burning, aching, or stabbing pain in a dermatomal distribution (often before any rash appears, leading to diagnostic uncertainty during this phase); followed by the eruption of grouped vesicles on an erythematous base in a unilateral dermatomal pattern, most commonly affecting the thoracic dermatomes (50-70% of cases) or the ophthalmic division of the trigeminal nerve (herpes zoster ophthalmicus, 10-15% of cases). The rash progresses from vesicles to pustules to crusts over 7-10 days and is typically accompanied by moderate to severe pain. Post-herpetic neuralgia (PHN) — defined as pain persisting more than 90 days after rash onset — is the most significant complication, occurring in approximately 10-15% of all zoster cases and in 25-50% of those over age 70; PHN causes severe, debilitating pain that is notoriously difficult to manage and substantially impairs quality of life.

Antiviral therapy with acyclovir, valacyclovir, or famciclovir initiated within 72 hours of rash onset reduces the severity and duration of the acute zoster episode and substantially reduces the risk and severity of PHN. Valacyclovir (1000 mg three times daily for 7 days) and famciclovir (500 mg three times daily for 7 days) are preferred over acyclovir because of their higher oral bioavailability, simpler dosing, and comparable efficacy. In Ontario’s minor ailment framework, pharmacists can prescribe antivirals for herpes zoster in immunocompetent adults under defined protocols; recognition of referral triggers — ophthalmic involvement (requiring urgent ophthalmological assessment), disseminated disease (more than one non-contiguous dermatome, involving more than 20 lesions outside the primary dermatome, systemic symptoms), immunocompromised status, and severe pain requiring parenteral treatment — is essential for safe pharmacist management.

Chapter 7: Special Populations in Self-Care — Frailty and OTC Drug Safety

Nonprescription Drug Use in Frail Individuals

Frailty is a geriatric syndrome characterized by diminished physiological reserve across multiple organ systems, leading to increased vulnerability to stressors and adverse outcomes. Frailty exists on a continuum — the Clinical Frailty Scale (CFS) developed by Rockwood and colleagues provides a 9-point scale from “very fit” (CFS 1) to “terminally ill” (CFS 9) — and its prevalence increases dramatically with age, affecting approximately 25% of community-dwelling adults over 85. Frail older adults are particularly vulnerable to adverse effects from nonprescription drugs for multiple reasons: age-related pharmacokinetic changes (reduced renal clearance, reduced hepatic metabolism, decreased plasma albumin, increased volume of distribution for lipophilic drugs, reduced volume of distribution for hydrophilic drugs), pharmacodynamic hypersensitivity (increased sensitivity to CNS and cardiovascular effects of many drugs), polypharmacy (multiple drug interactions), and reduced homeostatic reserve (impaired ability to compensate for drug-induced perturbations in blood pressure, fluid balance, glucose, or electrolytes).

The Beers Criteria (American Geriatrics Society, updated 2023) and the STOPP/START criteria (O’Mahony et al., updated 2023) provide evidence-based frameworks for identifying potentially inappropriate medications in older adults. Many drugs that are freely available OTC are specifically flagged by these criteria as potentially inappropriate for use in older, particularly frail, individuals. Diphenhydramine (Benadryl) — an older first-generation antihistamine widely used for allergy, insomnia, and motion sickness — is listed in the Beers Criteria as potentially inappropriate in older adults due to its potent anticholinergic effects: sedation, cognitive impairment (increased risk of delirium in susceptible individuals), urinary retention (potentially catastrophic in men with benign prostatic hyperplasia), constipation, dry mouth, blurred vision, and orthostatic hypotension. First-generation antihistamines and other anticholinergic drugs have additive CNS effects that substantially increase the risk of falls and fractures in frail older adults, who are already at high risk due to muscle weakness, gait instability, and postural hypotension.

NSAIDs — widely used OTC for pain and inflammation — carry particular risks in frail older adults. Gastrointestinal toxicity (peptic ulcer disease, upper GI bleeding) from NSAIDs increases significantly with age; renal toxicity (NSAID-induced acute kidney injury from prostaglandin-dependent renal blood flow impairment) is especially dangerous in frail patients who may have pre-existing CKD, reduced intravascular volume from diuretic use, or reduced physiological reserve to compensate for renal insults; cardiovascular risk (fluid retention, increased blood pressure, proarrhythmic effects) is amplified in patients with pre-existing heart failure or hypertension. Acetaminophen, at appropriate doses (maximum 3 g/day in older adults, or 2 g/day in those with significant alcohol use or liver disease), is generally safer than NSAIDs for pain management in frail older adults for most indications.

OTC Drugs of Abuse Potential

Several nonprescription products have significant potential for misuse, abuse, and dependence — a consideration that is relevant both to patient safety counselling and to pharmacy operations management (appropriate storage, sale monitoring, and identification of misuse patterns). The most clinically significant categories are pseudoephedrine-containing decongestants, dextromethorphan, and codeine-containing analgesics.

Pseudoephedrine, a sympathomimetic decongestant used in products such as Sudafed, has been diverted for the illegal manufacture of methamphetamine. In Canada and the United States, pseudoephedrine-containing products are stored behind the pharmacy counter (Schedule II status in Canada under the NAPRA NDSS), and pharmacists should be alert to patterns of purchasing that suggest diversion — purchases by multiple individuals in rapid succession, individuals purchasing at or near the quantity limit, or unusual purchase patterns. Dextromethorphan (DXM), the antitussive present in many OTC cough preparations (Robitussin DM, Nyquil, Benylin DM, and many others) has significant abuse potential at doses five to ten times the therapeutic dose, producing dissociative and hallucinogenic effects mediated through NMDA receptor antagonism, sigma-1 receptor agonism, and serotonergic activity. DXM abuse (called “robotripping” in lay terminology) is particularly common among teenagers. Pharmacists should be alert to purchase patterns suggesting DXM abuse and should counsel patients, particularly parents of adolescents, about safe storage and the risks of DXM misuse.

Chapter 8: Wellness Strategies and Pharmacist Well-Being

Integrating Wellness into Self-Care Consultations

The contemporary model of pharmacist-patient interaction in the self-care context is shifting from a transactional, product-centred model (“here is the OTC product for your symptom”) toward a more holistic, person-centred model that acknowledges the interconnectedness of physical symptoms, lifestyle factors, mental health, and social determinants of health. Pharmacists who can engage authentically with patients about the broader context of their self-care concerns — asking about sleep quality, stress levels, dietary patterns, physical activity, social support — and who can integrate evidence-based wellness strategies alongside conventional pharmacological recommendations, provide care that is both more effective and more aligned with what patients value.

Sleep disturbance is one of the most prevalent wellness concerns in the Canadian population, with an estimated 40% of adults reporting significant difficulty falling or staying asleep. Chronic sleep disturbance is associated with increased risk of cardiovascular disease, diabetes, obesity, depression, and impaired immune function, as well as immediate impairments in cognitive performance, mood, and quality of life. Pharmacists are frequently asked about OTC sleep aids, and the evidence-based response requires balancing the desire to provide immediate relief with the recommendation that addresses the root cause. Diphenhydramine and doxylamine — the active ingredients in most OTC sleep aids (Benadryl, Unisom, Nytol, ZzzQuil, Sleepinal) — are first-generation antihistamines with sedative properties due to their H1 receptor antagonism and anticholinergic effects; they produce rapid onset of sedation but are associated with next-morning grogginess, tolerance developing within a few days of regular use (reducing their effectiveness as a chronic sleep aid), and the significant anticholinergic risks described above in the section on frail older adults. They should be recommended only for short-term, occasional use in appropriate patients.

The most evidence-based treatment for chronic insomnia is Cognitive Behavioural Therapy for Insomnia (CBT-I) — a structured behavioral and cognitive intervention that addresses the thoughts, behaviors, and arousal patterns that perpetuate insomnia, independent of its original cause. CBT-I produces durable improvements in sleep quality and quantity that persist after treatment ends, unlike pharmacological sleep aids whose effects wane with tolerance and return to baseline when discontinued. Pharmacists are well-positioned to briefly introduce the core CBT-I principles — sleep restriction therapy (temporarily restricting time in bed to build sleep pressure), stimulus control (associating the bed only with sleep), sleep hygiene education, and cognitive restructuring — and to direct patients to CBT-I resources such as the Insomnia Coach app (free, from the US Department of Veterans Affairs) or Canadian digital CBT-I programs.

Chapter 9: Evidence-Based Practice and Clinical Resource Development

Creating Clinical Resources for Minor Ailment Practice

An important applied competency developed in PHARM 362 — assessed through the Minor Ailment Prescribing Assignment — is the ability to synthesize the best available evidence into a practical, pharmacist-facing clinical resource (such as an assessment algorithm, a decision guide, or a patient education tool) that supports high-quality, consistent minor ailment management. This competency integrates drug information skills (identifying and critically appraising the evidence), clinical knowledge (understanding the pathophysiology and clinical features of the condition), and communication skills (translating complex evidence into clear, practical guidance).

An effective clinical algorithm for minor ailment assessment typically has the following components: (1) a clear list of inclusion criteria (symptoms and patient characteristics consistent with the minor ailment) and exclusion criteria (features that mandate referral); (2) a systematic assessment framework (using SCHOLAR-MAC or an equivalent structured approach); (3) specific “red flag” symptoms organized to facilitate rapid identification; (4) evidence-based first-line treatment recommendations with dosing, duration, and counselling points; (5) patient education content covering medication use, non-pharmacological measures, expected response, and follow-up guidance; and (6) documentation prompts that ensure the clinical encounter is adequately recorded.

The process of developing a clinical resource for an assigned minor ailment requires applying the systematic drug information skills developed in PHARM 155: searching the primary and secondary literature using PICO-structured search strategies, critically appraising the identified evidence using validated appraisal tools, synthesizing the evidence into graded recommendations, and acknowledging uncertainty transparently. Resources must be based on current evidence and Canadian-specific guidelines wherever available. The group process of developing these resources also develops the interprofessional collaboration and communication skills that are central to contemporary pharmacy practice — working effectively in a team, managing disagreements constructively, dividing tasks according to individual strengths, and integrating diverse perspectives into a unified, high-quality product.

The Future of Minor Ailment Practice in Canada

The trajectory of minor ailment prescribing in Canada is strongly upward — more conditions, more provinces, more integrated service models, and more robust evidence of pharmacist competence and patient benefit. The National Pharmacist Prescribing Initiative, advanced by the Canadian Pharmacists Association and supported by provincial associations, aims to harmonize and expand pharmacist prescribing authority across all provinces, reducing the current interprovincial variability in scope that creates confusion for pharmacists who practice across provincial boundaries or who work in border communities.

As the evidence base for pharmacist minor ailment prescribing accumulates — through pharmacist-generated real-world outcome data from electronic medical record integrations, through controlled evaluations of specific prescribing programs, and through patient experience research — the clinical and economic case for further expansion becomes increasingly compelling. Pharmacists who invest in developing and demonstrating clinical competency in the conditions currently authorized for prescribing, who document their clinical encounters in ways that generate usable outcome data, and who engage proactively with provincial governments and regulatory authorities in the policy discussions that will shape the next wave of scope expansion are the architects of the profession’s future. PHARM 362 is the course that develops the clinical foundations for that future.